Dixian Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dixian Luo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Yao Shen
Laboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital, The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, P. R. China
3 shared publicationsAilin Qiu
Laboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital, The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, P. R. China
2 shared publications- Dennis K. P. Ng
Department of Chemistry The Chinese University of Hong Kong Hong Kong China
2 shared publications Evelyn Y. Xue
Department of Chemistry The Chinese University of Hong Kong Shatin, N.T. Hong Kong 999077 China
2 shared publicationsGun Yang
Department of Laboratory Medicine Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) Shenzhen University Shenzhen 518052 China
2 shared publicationsQingshuang Zou
Department of Chemistry The Chinese University of Hong Kong Shatin, N.T. Hong Kong 999077 China
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Cancer Cell International
AKR1B10 mediates glycolysis and proliferation in breast cancer via the IGF2R-PGK1-H4K12la-mTOR signaling axis
- 24 August 2026
- Published by Springer Nature in Cancer Cell International
Open AccessAKR1B10 mediates glycolysis and proliferation in breast cancer via the IGF2R-PGK1-H4K12la-mTOR signaling axis
- Open Access
- 27 February 2026
- Published by Elsevier in Food Chemistry
- Vol. 510, 148676
Discovery and screening of thermostable signature peptides for robust quantification of wheat allergens in processed foods
- 27 February 2026
- Published by Elsevier in Food Chemistry
- Vol. 510, 148676
Open AccessDiscovery and screening of thermostable signature peptides for robust quantification of wheat allergens in processed foods
- Open Access
- 29 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A novel four-serum marker model for early detection and therapeutic monitoring of breast cancer
Early diagnosis of breast cancer (BC) remains pivotal for enhancing patient outcomes, yet current imaging modalities face inherent limitations. This retrospective study, encompassing 1366 BC patients and 1186 healthy controls (HC) from Shenzhen Nanshan People’s Hospital (2022–2025), developed and validated a serum tumor marker-based predictive model to address this gap. Eight markers—CEA, AFP, CA199, CA242, CA15-3, CA125, FER, and NSE—were analyzed, with multivariate logistic regression identifying AFP, CA242, CA15-3, and NSE as independent diagnostic predictors. The resulting four-marker panel demonstrated robust performance, achieving an AUC of 0.90 (95% CI: 0.89–0.92) with 77.3% sensitivity and 89.7% specificity in the development cohort (n = 1535), and sustained efficacy in validation (AUC = 0.82, 87.5% sensitivity, 72.8% specificity; n = 761). The model effectively stratified early-stage (T1/T2: 86.49% accuracy) versus advanced-stage (T3/T4: 92.00%) tumors, lymph node involvement (N0: 86.49%; N+: 88.00%), metastatic status (M0: 87.32%; M+: 85.71%), and molecular subtypes (Luminal A: 91.33%; Luminal B: 82.35%; HER2+: 84.61%; triple-negative: 87.75%). Notably, longitudinal risk score trends correlated with therapeutic response, declining in remission and rising with progression. These findings collectively highlight the model’s dual utility as a high-accuracy diagnostic tool for early BC detection and a dynamic biomarker for monitoring treatment efficacy. This novel model may provide an auxiliary approach in current screening paradigms, underscoring its transformative potential in oncology practice.
- 29 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA novel four-serum marker model for early detection and therapeutic monitoring of breast cancer
Early diagnosis of breast cancer (BC) remains pivotal for enhancing patient outcomes, yet current imaging modalities face inherent limitations. This retrospective study, encompassing 1366 BC patients and 1186 healthy controls (HC) from Shenzhen Nanshan People’s Hospital (2022–2025), developed and validated a serum tumor marker-based predictive model to address this gap. Eight markers—CEA, AFP, CA199, CA242, CA15-3, CA125, FER, and NSE—were analyzed, with multivariate logistic regression identifying AFP, CA242, CA15-3, and NSE as independent diagnostic predictors. The resulting four-marker panel demonstrated robust performance, achieving an AUC of 0.90 (95% CI: 0.89–0.92) with 77.3% sensitivity and 89.7% specificity in the development cohort (n = 1535), and sustained efficacy in validation (AUC = 0.82, 87.5% sensitivity, 72.8% specificity; n = 761). The model effectively stratified early-stage (T1/T2: 86.49% accuracy) versus advanced-stage (T3/T4: 92.00%) tumors, lymph node involvement (N0: 86.49%; N+: 88.00%), metastatic status (M0: 87.32%; M+: 85.71%), and molecular subtypes (Luminal A: 91.33%; Luminal B: 82.35%; HER2+: 84.61%; triple-negative: 87.75%). Notably, longitudinal risk score trends correlated with therapeutic response, declining in remission and rising with progression. These findings collectively highlight the model’s dual utility as a high-accuracy diagnostic tool for early BC detection and a dynamic biomarker for monitoring treatment efficacy. This novel model may provide an auxiliary approach in current screening paradigms, underscoring its transformative potential in oncology practice.
- Open Access
- 24 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2410537
Fabrication of Polydopamine‐Coated High‐Entropy MXene Nanosheets for Targeted Photothermal Anticancer Therapy
Transition metal carbides, nitrides, and carbonitrides (MXenes) have emerged as a promising class of 2D materials that can be used for various applications. Recently, a new form of high‐entropy MXenes has been reported, which contains an increased number of elemental species that can increase the configurational entropy and reduce the Gibbs free energy. The unique structure and composition lead to a range of intriguing and tunable characteristics. Herein, the fabrication of high‐entropy MXene TiVNbMoC3Tx (T = surface terminations) with a layer of polydopamine is reported, followed by immobilization of a phthalocyanine‐based fluorophore for imaging and the peptide sequence QRHKPREGGGSC for targeting the epidermal growth factor receptor (EGFR) overexpressed in cancer cells. The resulting nanocomposite exhibits high biocompatibility and superior photothermal property. Upon laser irradiation at 808 nm, the light‐to‐heat conversion efficiency is up to 56.1%, which is significantly higher than that of conventional 2D materials. In vitro studies show that these nanosheets could be internalized selectively into EGFR‐positive cancer cells and effectively eliminate these cells mainly through photothermal‐induced apoptosis. Using 4T1 tumor‐bearing mice as an animal model, the nanosheets could accumulate at the tumor and effectively eradicate the tumor upon laser irradiation without causing noticeable adverse effects to the mice.
- 24 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2410537
Open AccessFabrication of Polydopamine‐Coated High‐Entropy MXene Nanosheets for Targeted Photothermal Anticancer Therapy
Transition metal carbides, nitrides, and carbonitrides (MXenes) have emerged as a promising class of 2D materials that can be used for various applications. Recently, a new form of high‐entropy MXenes has been reported, which contains an increased number of elemental species that can increase the configurational entropy and reduce the Gibbs free energy. The unique structure and composition lead to a range of intriguing and tunable characteristics. Herein, the fabrication of high‐entropy MXene TiVNbMoC3Tx (T = surface terminations) with a layer of polydopamine is reported, followed by immobilization of a phthalocyanine‐based fluorophore for imaging and the peptide sequence QRHKPREGGGSC for targeting the epidermal growth factor receptor (EGFR) overexpressed in cancer cells. The resulting nanocomposite exhibits high biocompatibility and superior photothermal property. Upon laser irradiation at 808 nm, the light‐to‐heat conversion efficiency is up to 56.1%, which is significantly higher than that of conventional 2D materials. In vitro studies show that these nanosheets could be internalized selectively into EGFR‐positive cancer cells and effectively eliminate these cells mainly through photothermal‐induced apoptosis. Using 4T1 tumor‐bearing mice as an animal model, the nanosheets could accumulate at the tumor and effectively eradicate the tumor upon laser irradiation without causing noticeable adverse effects to the mice.
- Open Access
- 1 July 2024
- Published by Wiley in Advanced Materials
- Vol. 37 (2) , 2407425
Photo‐metallo‐immunotherapy: Fabricating Chromium‐Based Nanocomposites to Enhance CAR‐T Cell Infiltration and Cytotoxicity against Solid Tumors
The infiltration and cytotoxicity of chimeric antigen receptor (CAR)‐T cells are crucial for effective elimination of solid tumors. While metallo‐immunotherapy is a promising strategy that can activate the antitumor immunity, its role in promoting CAR‐T cell therapy remains elusive. The first single‐element nanomaterial based on chromium nanoparticles (Cr NPs) for cancer photo‐metallo‐immunotherapy has been reported previously. Herein, an extended study using biodegradable polydopamine as a versatile carrier for these nanoparticles, enabling synergistic CAR‐T cell therapy, is reported. The results show that these nanocomposites with or without further encapsulation of the anticancer drug alpelisib can promote the CAR‐T cell migration and antitumor effect. Upon irradiation with near‐infrared light, they caused mild hyperthermia that can “warm” the “cold” tumor microenvironment (TME). The administration of B7‐H3 CAR‐T cells to NOD severe combined immunodeficiency gamma mice bearing a human hepatoma or PIK3CA‐mutated breast tumor can significantly inhibit the tumor growth after the induction of tumor hyperthermia by the nanocomposites and promote the secretion of serum cytokines, including IL‐2, IFN‐γ, and TNF‐α. The trivalent Cr3+ ions, which are the major degradation product of these nanocomposites, can increase the CXCL13 and CCL3 chemokine expressions to generate tertiary lymphoid structures (TLSs) in the tumor tissues, facilitating the CAR‐T cell infiltration.
- 1 July 2024
- Published by Wiley in Advanced Materials
- Vol. 37 (2) , 2407425
Open AccessPhoto‐metallo‐immunotherapy: Fabricating Chromium‐Based Nanocomposites to Enhance CAR‐T Cell Infiltration and Cytotoxicity against Solid Tumors
The infiltration and cytotoxicity of chimeric antigen receptor (CAR)‐T cells are crucial for effective elimination of solid tumors. While metallo‐immunotherapy is a promising strategy that can activate the antitumor immunity, its role in promoting CAR‐T cell therapy remains elusive. The first single‐element nanomaterial based on chromium nanoparticles (Cr NPs) for cancer photo‐metallo‐immunotherapy has been reported previously. Herein, an extended study using biodegradable polydopamine as a versatile carrier for these nanoparticles, enabling synergistic CAR‐T cell therapy, is reported. The results show that these nanocomposites with or without further encapsulation of the anticancer drug alpelisib can promote the CAR‐T cell migration and antitumor effect. Upon irradiation with near‐infrared light, they caused mild hyperthermia that can “warm” the “cold” tumor microenvironment (TME). The administration of B7‐H3 CAR‐T cells to NOD severe combined immunodeficiency gamma mice bearing a human hepatoma or PIK3CA‐mutated breast tumor can significantly inhibit the tumor growth after the induction of tumor hyperthermia by the nanocomposites and promote the secretion of serum cytokines, including IL‐2, IFN‐γ, and TNF‐α. The trivalent Cr3+ ions, which are the major degradation product of these nanocomposites, can increase the CXCL13 and CCL3 chemokine expressions to generate tertiary lymphoid structures (TLSs) in the tumor tissues, facilitating the CAR‐T cell infiltration.